Form 8.5 (EPT/RI) - Yourgene Health plc Amended

RNS Number: 0863F Stifel Nicolaus Europe Limited 05 July 2023 FORM 8.5 (EPT/RI) **REPLACEMENT** The Form 8.5 (EPT/RI) -Yourgene Health plc announcement released on 05/07/2023 under RNS No 0593F has been amended. Amendments are identified with an asterisk (*). FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS **DEALING IN A CLIENT-SERVING CAPACITY** Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION Stifel Nicolaus Europe (a) Name of exempt principal trader: Limited (b) Name of offeror/offeree in relation to whose relevant securities this form relates: Yourgene Health plc Use a separate form for each offeror/offeree (c) Name of the party to the offer with which exempt principal trader is connected: Yourgene Health plc

04 July 2023

N/A

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

(e) In addition to the company in 1(b) above, is the exempt principal trader making

(d) Date dealing undertaken:

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary	Buy	21,248,704	0.485* GBX	0.4696* GBX
Ordinary	Sell	20,986,390	0.494* GBX	0.485* GBX

(b) Cash-settled derivative transactions

Class of	Product	Nature of dealing	Number of	Price per
relevant	description	e.g. opening/closing a long/short position,	reference securities	1
security	e.g. CFD	increasing/reducing a long/short position	reference securities	unit

- (c) Stock-settled derivative transactions (including options)
- (i) Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
----------------------------	--	---	--	-------------------------------	--	----------------	---

(ii) Exercise

Class of relevant security	Product desc e.g. call optic	•	Exercising/ exercised against	Numbe	er of securities	Exercise price per unit
(d) Other dealings (inc	luding subscr	ibing foi	r new securities)			
· · · · · · · · · · · · · · · · · · ·	•		·			
Class of relevant secu		nture of o	dealing ription, conversion	Details	Price per unit	(if applicable)
3. OTHER INFORMATION	ON					
○ · · · · · · · · · · · · · · · · · · ·	•					
(a) Indemnity and other	er dealing arra	ngemen	nts			
D.A. H. of analysis days					. Post formal	a to former lands at one had
relevant securities wh	ich may be an	n induce	nent, or any agreement on	rom dealing	entered into b	y the exempt
offer: Irrevocable commitme	ents and lette	rs of inte	ent should not be includ		-	
arrangements or unde	erstandings, st	tate "noi	ne"			
None						
(b) Agreements, arrang	gements or ur	nderstan	ndings relating to option	s or derivati	ves	
making the disclosure	e and any othe	er persor		informal, b	etween the exe	empt principal trader
			es under any option; or disposal of any relevan	t securities	to which any d	erivative is
	greements, arı	rangeme	ents or understandings,	state "none	II	

None

Date of disclosure: 05 July 2023
Contact name: Joseph Hamshare
Telephone number: 02034651195

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

FERMZGGNZKKGFZM